Synairgen Ltd formerly known as Synairgen PLC is a United Kingdom-based company, which is a respiratory drug discovery and development company. Its specialist respiratory biotech company primary focus is developing investigative inhaled interferon beta for the treatment of severe viral lung infections as potentially the broad-spectrum antiviral treatment delivered directly into the lungs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Net sales - Rate of surprise

Company calendar

Delayed OTC Markets 09:35:51 2026-03-09 EDT			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	+9,900.00%

08-18	Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
08-17	Synairgen plc Auditor Raises 'Going Concern' Doubt	CI

Market Cap	82.32K 112K 96.11K 89.92K 154K 10.73M 157K 1.06M 414K 5.39M 421K 412K 17.84M	P/E 2024	-0.67x	P/E 2025	-
Enterprise Value	-12.45M -16.97M -14.54M -13.6M -23.36M -1.62B -23.67M -161M -62.66M -816M -63.72M -62.33M -2.7B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	17.82%	Yield 2024 *	-	Yield 2025	-

08-18	Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
08-17	Synairgen plc Auditor Raises 'Going Concern' Doubt	CI
04-01	Synairgen Limited Announces Termination of John Bradshaw as Director, Effective March 31, 2026	CI
04-01	Synairgen Limited Announces Termination of Director Martin Patrick Murphy, Effective March 31, 2026	CI
02-26	Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical Study	CI
12-08	Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical Study	CI
25-10-01	Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-09-30	Synairgen plc Auditor Raises 'Going Concern' Doubt	CI
25-09-04	Synairgen plc Provides Business Update	CI
25-05-16	Synairgen plc Announces Chief Executive Officer Changes	CI
25-05-16	Synairgen plc Announces Transition of Mark Parry-Billings to Executive Chairman, Effective 1 July 2025	CI
25-05-16	Synairgen plc Announces Step Down of Joseph Colliver as Chief Financial Officer	CI
25-05-01	Synairgen plc Announces Appointment of John Bradshaw to the Board as an Independent Non-Executive Director and Chair of the Audit Committee, Effective 1 May 2025	CI

Current year	0		0
1 year	0		0
3 years	0		0.14
5 years	0		2.88
10 years	0		3.4

Synairgen plc Stock

Stocks

SYGGF

GB00B0381Z20

Biotechnology & Medical Research

Valuation: Synairgen plc

Chart: Synairgen plc

Latest news : Synairgen plc

Quotes and Performance

Course Extremes

Managers and Directors: Synairgen plc

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Net sales - Rate of surprise

Manager	Title	Age	Since
Joseph Colliver CEO	Chief Executive Officer	46	2025-06-30
Andy Lee DFI	Director of Finance/CFO	-	-
Marcin Mankowski CTO	Chief Tech/Sci/R&D Officer	-	2023-10-02

Director	Title	Age	Since
Joseph Colliver BRD	Director/Board Member	46	2023-11-05
Mark Parry-Billings CHM	Chairman	-	2024-10-09
Martin Murphy BRD	Director/Board Member	57	2025-01-15

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/15/23	Joseph Colliver	Free	Chief Executive Officer	750,000	0.3724%
11/15/23	Marcin Mankowski	Free	Chief Technology Officer	750,000	0.3724%
7/6/22	John Ward	Free	Chief Financial Officer	387,931	0.1926%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNAIRGEN PLC	-.--%	-.--%	-.--%	-99.91%	110K
LONZA GROUP AG	+1.09%	+5.26%	+4.44%	+26.03%	51.22B
REVOLUTION MEDICINES, INC.	-1.07%	+2.12%	+470.26%	+596.45%	45.38B
BEONE MEDICINES AG	+1.84%	+8.03%	+19.57%	+91.41%	41.97B
IQVIA HOLDINGS INC.	+1.57%	+9.82%	+40.19%	+21.24%	42.15B
CELLTRION, INC.	-0.93%	-4.80%	+17.39%	+46.60%	31.95B
ASCENDIS PHARMA A/S	-0.47%	+2.98%	-	-	16.73B
MEDPACE HOLDINGS, INC.	+1.28%	+7.54%	+37.23%	+152.91%	17.1B
EUROFINS SCIENTIFIC SE	+0.03%	+3.91%	+5.84%	+35.04%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.33%	+5.69%	+91.52%	+47.32%	13.91B
Average	+0.51%	+2.87%	+76.27%	+101.90%	27.52B
Weighted average by Cap.	+0.48%	+3.13%	+103.06%	+148.63%

	2024	2025
Net sales	-	-
Net income	-6.81M -9.28M -7.95M -7.44M -12.78M -888M -12.95M -87.91M -34.28M -446M -34.86M -34.1M -1.48B	-12.13M -16.53M -14.16M -13.25M -22.77M -1.58B -23.07M -157M -61.06M -795M -62.09M -60.73M -2.63B
Net Debt	-4.55M -6.21M -5.32M -4.97M -8.55M -594M -8.66M -58.78M -22.92M -298M -23.31M -22.8M -987M	-12.53M -17.08M -14.63M -13.69M -23.52M -1.63B -23.83M -162M -63.08M -821M -64.14M -62.74M -2.72B